$4.10
-0.15 (-3.63%)
Open$4.14
Previous Close$4.25
Day High$4.16
Day Low$4.09
52W High$14.73
52W Low$3.10
Volume—
Avg Volume34.1K
Market Cap30.97M
P/E Ratio—
EPS$-3.07
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+651.7% upside
Current
$4.10
$4.10
Target
$30.82
$30.82
$21.30
$30.82 avg
$34.43
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.77M | 10.40M | 9.97M |
| Net Income | -34,356,212 | 1.68M | 1.79M |
| Profit Margin | -1,940.2% | 16.1% | 17.9% |
| EBITDA | -34,210,763 | 3.32M | 3.17M |
| Free Cash Flow | — | 838.7K | 1.16M |
| Rev Growth | — | +2.0% | -1.5% |
| Debt/Equity | — | 0.33 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |